Docetaxel-Loaded Disulfide Cross-Linked Nanoparticles Derived from Thiolated Sodium Alginate for Colon Cancer Drug Delivery - PubMed (original) (raw)

Docetaxel-Loaded Disulfide Cross-Linked Nanoparticles Derived from Thiolated Sodium Alginate for Colon Cancer Drug Delivery

Hock Ing Chiu et al. Pharmaceutics. 2020.

Abstract

In this study, fluorescein-labelled wheat germ agglutinin (fWGA)-conjugated disulfide cross-linked sodium alginate nanoparticles were developed to specifically target docetaxel (DTX) to colon cancer cells. Different amounts of 3-mercaptopropionic acid (MPA) were covalently attached to sodium alginate to form thiolated sodium alginate (MPA1-5). These polymers were then self-assembled and air-oxidised to form disulfide cross-linked nanoparticles (MP1-5) under sonication. DTX was successfully loaded into the resulting MP1-5 to form DTX-loaded nanoparticles (DMP1-5). DMP2 had the highest loading efficiency (17.8%), thus was chosen for fWGA surface conjugation to form fWGA-conjugated nanoparticles (fDMP2) with a conjugation efficiency of 14.1%. Transmission electron microscopy (TEM) and scanning electron microscopy (SEM) analyses showed spherical nanoparticles, and an in vitro drug release study recorded a cumulative drug release of 48.6%. Dynamic light scattering (DLS) analysis revealed a mean diameter (MD) of 289 nm with a polydispersity index (PDI) of 0.3 and a zeta potential of -2.2 mV for fDMP2. HT-29 human colon cancer cells treated with fDMP2 showed lower viability than that of L929 mouse fibroblast cells. These results indicate that fDMP2 was efficiently taken up by HT-29 cells (29.9%). Fluorescence and confocal imaging analyses also showed possible internalisation of nanoparticles by HT-29 cells. In conclusion, fDMP2 shows promise as a DTX carrier for colon cancer drug delivery.

Keywords: HT-29; disulfide cross-linked nanoparticles; docetaxel; thiolated sodium alginate; wheat germ agglutinin conjugation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Scheme 1

Scheme 1

Synthetic scheme of (A) MPA and (B) assembly process of disulfide cross-linked nanoparticles.

Scheme 1

Scheme 1

Synthetic scheme of (A) MPA and (B) assembly process of disulfide cross-linked nanoparticles.

Figure 1

Figure 1

FTIR spectra of sodium alginate, MPA and MP.

Figure 2

Figure 2

1H-NMR spectra of (A) sodium alginate and (B) MPA.

Figure 3

Figure 3

Comparison of the concentrations of thiol between MPA polymers and MP nanoparticles (mean ± SD, n = 3); ** (p < 0.01) and * (p < 0.05) indicate significant differences between the samples.

Figure 4

Figure 4

SEM micrographs of (A) MP2, (C) DMP2, (E) fDMP2; and TEM micrographs of (B) MP2, (D) DMP2, (F) fDMP2.

Figure 5

Figure 5

pH sensitivity profiles of (A) MP1–5 and (B) fMP2 (mean ± SD, n = 3).

Figure 6

Figure 6

In vitro drug release profile of (A) DMP2 and (B) fDMP2 in control media (GSH-free) and in stimulated gastrointestinal media (with GSH) at predetermined pH and time (mean ± SD, n = 3); * (p < 0.05) indicates that significant differences were observed between the samples.

Figure 7

Figure 7

Comparison of effects of fMP2, fDMP2, and DTX on (A) HT-29 cells and (B) L929 cells (mean ± SD, n = 3); the samples with same alphabets a–r indicate significant difference between them, while, sample with * indicates (p < 0.05) compared to untreated cells.

Figure 8

Figure 8

Cellular uptake profile of fDMP2 by HT-29 cells as a function of (A) incubation time and (B) concentration over an incubation period of 2 h (mean ± SD, n = 3); ** indicates p < 0.01 between the two time intervals.

Figure 9

Figure 9

Cellular uptake of fDMP2 by HT-29 cells (2 h) under 40,000 × magnifications illustrated by fluorescence microscopy.

Figure 10

Figure 10

Colocalisation of clathrin for fDMP2 in HT-29 cells; localisation of clathrin, nucleus, nanoparticles, and the merged image in HT-29 cells.

Similar articles

Cited by

References

    1. Azizah A.M., Nor Saleha I.T., Noor Hashimah A., Asmah Z.A., Mastulu W. Malaysian National Cancer Registry Report 2007-2011. National Cancer Institute, Ministry of Health; Putrajaya, Malaysia: 2016. pp. 29–38.
    1. QUASAR Collaborative Group Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet. 2007;370:2020–2029. doi: 10.1016/S0140-6736(07)61866-2. - DOI - PubMed
    1. Desai P.P., Date A.A., Patravale V.B. Overcoming poor oral bioavailability using nanoparticle formulations—opportunities and limitations. Drug Discov. Today Technol. 2012;9:e87–e95. doi: 10.1016/j.ddtec.2011.12.001. - DOI - PubMed
    1. Conde J., Oliva N., Zhang Y., Artzi N. Local triple-combination therapy results in tumour regression and prevents recurrence in a colon cancer model. Nat. Mater. 2016;15:1128–1138. doi: 10.1038/nmat4707. - DOI - PMC - PubMed
    1. Philip A.K., Philip B. Colon targeted drug delivery systems: A review on primary and novel approaches. Oman Med. J. 2010;25:70–78. doi: 10.5001/omj.2010.24. - DOI - PMC - PubMed

LinkOut - more resources